Lexicon Pharma (LXRX) Misses Q3 EPS by 2c
Tweet
Share
E-mail
Get Alerts LXRX Hot Sheet
Price: $2.04 +0.99%
Revenue Growth %: -78.9%
Financial Fact:
Loss from operations: -34.93M
Today's EPS Names:
ALZN, ASPU, USAU, More
Revenue Growth %: -78.9%
Financial Fact:
Loss from operations: -34.93M
Today's EPS Names:
ALZN, ASPU, USAU, More
Join SI Premium – FREE
Lexicon Pharma (NASDAQ: LXRX) reported Q3 EPS of ($0.18), $0.02 worse than the analyst estimate of ($0.16). Revenue for the quarter came in at $1.75 million versus the consensus estimate of $2.92 million.
For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nucor projects Q3 2026 earnings above prior year, below estimates
- Allied Gold connects Kurmuk mine to Ethiopia's grid, feeds first ore
- StrategX closes second tranche, raising $198,000 in private placement
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
